144 related articles for article (PubMed ID: 3838513)
21. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.
Baczyk M; Junik R; Ziemnicka K; Sowiński J
Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495
[TBL] [Abstract][Full Text] [Related]
22. Acute myeloid leukemia after iodine-131 treatment for thyroid disorders.
Laurenti L; Salutari P; Sica S; Piccirillo N; Zini G; Zollino M; Leone G
Ann Hematol; 1998 Jun; 76(6):271-2. PubMed ID: 9692815
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic results of radioiodine therapy of hyperthyroid thyroid gland diseases].
Debrand-Passard A; Barzen G; Richter W; Wenzel KW; Felix R
Med Klin (Munich); 1994 Jun; 89(6):319-23. PubMed ID: 8072455
[TBL] [Abstract][Full Text] [Related]
24. Radiation dose in the selection of 131I or surgical treatment for toxic thyroid adenoma.
Gorman CA; Robertson JS
Ann Intern Med; 1978 Jul; 89(1):85-90. PubMed ID: 666197
[TBL] [Abstract][Full Text] [Related]
25. [Results of radioiodine therapy in different forms of hyperthyroidism in relation to the planned dosage].
Moser E
Aktuelle Radiol; 1992 Jul; 2(4):179-87. PubMed ID: 1504115
[TBL] [Abstract][Full Text] [Related]
26. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?
Jarløv AE; Hegedüs L; Kristensen LO; Nygaard B; Hansen JM
Clin Endocrinol (Oxf); 1995 Sep; 43(3):325-9. PubMed ID: 7586602
[TBL] [Abstract][Full Text] [Related]
27. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
28. Influence of iodine-131 dose on the outcome of hyperthyroidism in children.
Rivkees SA; Cornelius EA
Pediatrics; 2003 Apr; 111(4 Pt 1):745-9. PubMed ID: 12671107
[TBL] [Abstract][Full Text] [Related]
29. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
[TBL] [Abstract][Full Text] [Related]
30. [Results obtained in the treatment of hyperfunctional thyroid adenomas with I-131].
Holan T; Micluţia M; Derevenco V
Stud Cercet Endocrinol; 1972; 23(4):271-9. PubMed ID: 4681160
[No Abstract] [Full Text] [Related]
31. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
[TBL] [Abstract][Full Text] [Related]
32. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease.
Nordyke RA; Gilbert FI
J Nucl Med; 1991 Mar; 32(3):411-6. PubMed ID: 2005449
[TBL] [Abstract][Full Text] [Related]
33. [The influence of the galenic form of 131I administration on the results of radioiodine tests--comparison of 131I in capsules and in solutions (author's transl)].
Müller-Brand J; Staub JJ; Moeglen C; Peyer P
Nuklearmedizin; 1978 Apr; 17(2):70-3. PubMed ID: 78485
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
Coover LR; Silberstein EB; Kuhn PJ; Graves MW
J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
[TBL] [Abstract][Full Text] [Related]
35. Procedure guideline for therapy of thyroid disease with (131)iodine.
Meier DA; Brill DR; Becker DV; Clarke SE; Silberstein EB; Royal HD; Balon HR;
J Nucl Med; 2002 Jun; 43(6):856-61. PubMed ID: 12050333
[No Abstract] [Full Text] [Related]
36. Use of thyroid ultrasound volume in calculating radioactive iodine dose in hyperthyroidism.
Lucas KJ
Thyroid; 2000 Feb; 10(2):151-5. PubMed ID: 10718551
[TBL] [Abstract][Full Text] [Related]
37. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
[TBL] [Abstract][Full Text] [Related]
38. [Results of radioiodine treatment of patients with immunogenic and non-immunogenic hyperthyroidism using different focal doses].
Moser E; Pickardt CR; Mann K; Engelhardt D; Kirsch CM; Knesewitsch P; Tatsch K; Kreisig T; Kurz C; Saller B
Nuklearmedizin; 1988 Jun; 27(3):98-104. PubMed ID: 3405782
[TBL] [Abstract][Full Text] [Related]
39. A practical method for the estimation of therapeutic activity in the treatment of Graves' hyperthyroidism.
Panareo S; Rossi R; Fabbri S; De Paola G; Candini GC; Feggi L; Degli Uberti E
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):576-85. PubMed ID: 21068711
[TBL] [Abstract][Full Text] [Related]
40. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
Alexander EK; Larsen PR
J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
